Next 10 |
home / stock / hcm / hcm articles
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) tod...
U.S. stocks were mixed, with the Dow Jones gaining around 100 points on Thursday. Shares of Spectrum Brands Holdings, Inc. (NYSE:SPB) rose sharply ...
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nas...
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday. Shares of Hello Group Inc. (NASDAQ: MO...
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-exp...
Shares of SurgePays, Inc. (NASDAQ: SURG) fell sharply in today’s pre-market trading after the company reported worse-than-expected fourth-q...
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. Shares of The Beauty Health Company ...
U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 80 points on Wednesday. Shares of Airbnb, Inc. (NAS...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
4.59%Change Percent:
HUTCHMED (China) Limited Company Name:
HCM Stock Symbol:
NASDAQ Market:
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) tod...
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data rela...
— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s surufatinib and anti-PD-1 activity with Hengrui...